Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

In the Media

  • October 6, 2023

Podcast: Dr. Shane Johnson is guest on The Water Tower Hour (Live Recording from Benzinga Conference)

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour podcast. Host Jesse Redmond, Senior Analyst at Water Tower Research interviewed Shane live at the Benzinga Cannabis Capital Conference in Chicago September 28th.

In this interview, Shane talks about InMed and BayMedica’s rare cannabinoid expertise and the synergies between the two companies, the market opportunities for rare cannabinoids, the importance of cannabinoid consistency for consumer products and the challenges of the current cannabinoid landscape.

Shane Johnson enters the podcast at 25:50.

Highlights from Shane’s interview with Jesse:

  • 25:50 – Why attend Benzinga Cannabis Capital Conference? Who’s in attendance?
  • 27:10 – What do InMed and BayMedica specialize in? What are rare cannabinoids?
  • 28:00  – What is THCV? What is THCV used for?
  • 28:50 – What is considered a rare cannabinoid? What other cannabinoids, other than THC and CBD are found in higher quantities in the plant? Does BayMedica commercialize plant-based cannabinoids?
  • 31:15 – How are BayMedica’s and InMed’s businesses differentiated? Do InMed and BayMedica both focus on rare cannabinoids? How do the two businesses complement each other?
  • 33:30 – What are the market opportunities for rare cannabinoids in pharmaceutical and health and wellness. How are they different? What are the challenges for the cannabinoid business?
  • 35:20 – What is driving the recent revenue growth at InMed/BayMedica?
  • 37:20 – What does defined spectrum mean? Why are consumer interested in defined spectrum for their cannabinoid-based products? Why is cannabinoid consistency such an important quality in consumer products?
  • 40:00 – What are the biggest challenges facing the cannabinoid industry?
  • 44:20 – What is the 2024 outlook for BayMedica?

Podcast available on multiple platforms

Apple: https://podcasts.apple.com/us/podcast/the-water-tower-hour/id1693448305?i=1000630167209…
Google: https://podcasts.google.com/feed/aHR0cHM6Ly9mZWVkcy5idXp6c3Byb3V0LmNvbS8yMTc2NDc2LnJzcw/episode/QnV6enNwcm91dC0xMzcxMjg3MQ?sa=X&ved=0CAUQkfYCahcKEwigu8KixNyBAxUAAAAAHQAAAAAQAQ…
Spotify: https://open.spotify.com/show/65HhA2UPZVDW55kA3sCkXh…

Full Article
Source: The Water Tower Hour

Share this post

Latest Articles

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,

Read More
December 11, 2024

Study on Anti-Inflammation by Modulation of Endocannabinoid System

A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.

Read More
December 10, 2024

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

Read More
September 4, 2024
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*